TY - JOUR
T1 - Novel anemia therapies in chronic kidney disease
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - for Conference Participants
AU - Ku, Elaine
AU - Del Vecchio, Lucia
AU - Eckardt, Kai Uwe
AU - Haase, Volker H.
AU - Johansen, Kirsten L.
AU - Nangaku, Masaomi
AU - Tangri, Navdeep
AU - Waikar, Sushrut S.
AU - Więcek, Andrzej
AU - Cheung, Michael
AU - Jadoul, Michel
AU - Winkelmayer, Wolfgang C.
AU - Wheeler, David C.
AU - Afsar, Baris
AU - Akizawa, Tadao
AU - Anker, Stefan D.
AU - Arici, Mustafa
AU - Babitt, Jodie L.
AU - Barratt, Jonathan
AU - Berns, Jeffrey S.
AU - Besarab, Anatole
AU - Bhandari, Sunil
AU - Brown, Christopher
AU - Cases, Aleix
AU - Chertow, Glenn M.
AU - Delgado, Cynthia
AU - Drüeke, Tillman B.
AU - Fishbane, Steven
AU - Gómez, Rafael
AU - Grams, Morgan E.
AU - Hamano, Takayuki
AU - Hao, Chuan Ming
AU - Hsu, Raymond K.
AU - Iseki, Kunitoshi
AU - Jordans, Isabelle
AU - Lerma, Edgar V.
AU - Locatelli, Francesco
AU - Macdougall, Iain C.
AU - Małyszko, Jolanta
AU - Maxwell, Patrick
AU - McMahon, Lawrence P.
AU - Obrador, Gregorio T.
AU - Ostermann, Marlies
AU - Pecoits-Filho, Roberto
AU - Perwad, Farzana
AU - Roger, Simon D.
AU - Singh, Ajay K.
AU - Solá, Laura
AU - Spinowitz, Bruce S.
AU - Sugahara, Mai
N1 - Publisher Copyright:
© 2023 KDIGO: Kidney Disease Improving Global Outcomes
PY - 2023/10
Y1 - 2023/10
N2 - Anemia is common in patients with chronic kidney disease and is associated with a high burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline for the diagnosis and management of anemia in chronic kidney disease. Since then, new data from studies assessing established and emerging therapies for the treatment of anemia and iron deficiency have become available. Beginning in 2019, KDIGO planned 2 Controversies Conferences to review the new evidence and its potential impact on the management of anemia in clinical practice. Here, we report on the second of these conferences held virtually in December 2021, which focused on a new class of agents—the hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs). This report provides a review of the consensus points and controversies from this second conference and highlights areas that warrant prioritization for future research.
AB - Anemia is common in patients with chronic kidney disease and is associated with a high burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline for the diagnosis and management of anemia in chronic kidney disease. Since then, new data from studies assessing established and emerging therapies for the treatment of anemia and iron deficiency have become available. Beginning in 2019, KDIGO planned 2 Controversies Conferences to review the new evidence and its potential impact on the management of anemia in clinical practice. Here, we report on the second of these conferences held virtually in December 2021, which focused on a new class of agents—the hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs). This report provides a review of the consensus points and controversies from this second conference and highlights areas that warrant prioritization for future research.
KW - anemia
KW - chronic kidney disease
KW - dialysis
KW - erythropoiesis-stimulating agents
KW - hypoxia-inducible factor-prolyl hydroxylase inhibitors
KW - major adverse cardiovascular events
UR - http://www.scopus.com/inward/record.url?scp=85164321318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164321318&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2023.05.009
DO - 10.1016/j.kint.2023.05.009
M3 - Article
C2 - 37236424
AN - SCOPUS:85164321318
SN - 0085-2538
VL - 104
SP - 655
EP - 680
JO - Kidney international
JF - Kidney international
IS - 4
ER -